Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints
Shares tumbled premarket after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Open original sourceLoading market dashboard
Shares tumbled premarket after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Open original source